

1 Original Research:

2

3 **COVID-19 vaccine confidence and hesitancy among healthcare workers: a cross-sectional**  
4 **survey from a MERS-CoV experienced nation**

5

6 Mazin Barry<sup>1\*</sup>, Mohamad-Hani Temsah<sup>2\*</sup>, Abdullah Alhuzaimi<sup>6,7</sup>, Nurah Alamro, MD. DrPH.<sup>6,8</sup>,  
7 Ayman Al-Eyadhy<sup>2</sup>, MD, Fadi Aljamaan<sup>6,9,10</sup>, Basema Saddik<sup>11</sup>, Ali Alhaboob<sup>2</sup>, Fahad  
8 Alsohime<sup>2</sup>, Khalid Alhasan<sup>2</sup>, Abdulkarim Alrabiaah<sup>2</sup>, Ali Alaraj<sup>10,12</sup>, Rabih Halwani<sup>11</sup>, Amr  
9 Jamal<sup>6,8</sup>, Sarah Alsubaie<sup>2</sup>, Fatimah S. Al-Shahrani<sup>1</sup>, Ziad A. Memish<sup>13,14</sup>, Jaffar A. Al-Tawfiq<sup>3,4,5</sup>

10

- 11 1. Division of Infectious Diseases, Department of Internal Medicine, College of Medicine,  
12 King Saud University and King Saud University Medical City, Riyadh, Saudi Arabia
- 13 2. Pediatric Department, College of Medicine, , King Saud University, Riyadh, Saudi  
14 Arabia
- 15 3. Specialty Internal Medicine and Quality Department, Johns Hopkins Aramco Healthcare,  
16 Dhahran, Saudi Arabia
- 17 4. Infectious disease division, Department of Medicine, Indiana University School of  
18 Medicine, Indiana, USA
- 19 5. Infectious Disease Division, Department of Medicine, Johns Hopkins University School  
20 of Medicine, Baltimore, MD, USA
- 21 6. College of Medicine, King Saud University, Riyadh, Saudi Arabia
- 22 7. Division of Pediatric Cardiology, Cardiac Science Department, College of Medicine,  
23 King Saud University, Riyadh, Saudi Arabia
- 24 8. Department of Family and Community Medicine, King Saud University Medical City,  
25 Riyadh, Saudi Arabia
- 26 9. Critical Care Dept, College of Medicine, King Saud University, Riyadh, Saudi Arabia
- 27 10. Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia
- 28 11. College of Medicine, University of Sharjah, Sharjah, UAE
- 29 12. Department of Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia
- 30 13. Director Research and Innovation Centre, King Saud Medical City, Ministry of Health &  
31 College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia
- 32 14. Hubert Department of Global Health, Rollins School of Public Health, Emory University,  
33 Atlanta, GA, USA

34 \* First two authors contributed equally to this research

35 **Corresponding Author:**

36 Mazin Barry, MD  
37 College of Medicine, King Saud University  
38 PO Box 2925, Riyadh 11461  
39 Saudi Arabia  
40 Phone: +966 11 467 1039  
41 Email: [mbarry@ksu.edu.sa](mailto:mbarry@ksu.edu.sa)

1 **Word Count:**

2 Abstract: 236

3 Text: 2969

4 **Ethics approval and consent to participate:**

5 The study was approved by the Institutional Review Board at the College of Medicine and King  
6 Saud University Medical City (approval # 20/0065/IRB)

7 **Consent for publication:**

8 All authors gave their consent for publication.

9 **Availability of data and materials:**

10 All the data for this study will be made available upon reasonable request to the corresponding  
11 author.

12 **Funding:** None declared.

13 **Conflict of interest** None declared.

1 **Abstract**

2

3 **Objectives:** This study aimed to identify COVID-19 vaccine perception, acceptance, confidence,  
4 hesitancy, and barriers among healthcare workers (HCW).

5 **Methods:** An online national cross-sectional pilot-validated questionnaire was self-administered  
6 by HCW in Saudi Arabia, a nation with MERS-CoV experience. The main outcome variable was  
7 HCW's acceptance of COVID-19 vaccine candidates. The associated factors of vaccination  
8 acceptance were identified through a logistic regression analysis and the level of anxiety using  
9 generalized anxiety disorder 7.

10 **Result:** Out of 1512 HCWs who completed the study questionnaire—944 (62.4%) women and  
11 568 (37.6%) men—1058 (70%) were willing to receive COVID-19 vaccines. Logistic regression  
12 analysis revealed that male HCWs (ORa=1.551, 95% CI: 1.122–2.144), HCWs who believe in  
13 vaccine safety (ORa=2.151; 95% CI:1.708–2.708), HCWs who believe that COVID vaccines are  
14 the most likely way to stop the pandemic (ORa=1.539; 95% CI: 1.259–1.881), and HCWs who  
15 rely on Centers for Disease Control and Prevention website for COVID 19 updates (ORa=1.505,  
16 95% CI: 1.125–2.013) were significantly associated with reporting willingness to be vaccinated.  
17 However, HCWs who believed vaccines were rushed without evidence-informed testing were  
18 found to be 60% less inclined to accept COVID-19 vaccines (ORa=0.394, 95% CI: 0.298–  
19 0.522).

20 **Conclusion:** Most HCWs are willing to receive COVID-19 vaccines once available; yet,  
21 satisfactoriness of COVID-19 vaccination among HCWs is crucial because health professionals'  
22 knowledge and confidence toward vaccines are important determining factors for their own  
23 vaccine acceptance and recommendation to their patients.

24 **Keywords:** COVID-19, vaccine, acceptance, confidence, healthcare workers

## 1 **Introduction**

2

3 On December 31, 2019, a cluster of pneumonia cases was reported in Wuhan city, Hubei  
4 Province, China, and linked to a wet seafood market. Subsequently, a new coronavirus was  
5 identified as the etiological agent and named severe acute respiratory syndrome coronavirus-2  
6 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) [1-3]. The World  
7 Health Organization (WHO) International Health Regulation Emergency Committee declared  
8 COVID-19 a Public Health Emergency of International Concern on January 30, 2020, and a  
9 pandemic on March 11, 2020 [4].

10 As of November 29, 2020, COVID-19 has been reported globally in 191 countries, with  
11 62,311,483 laboratory-confirmed cases causing 1,453,467 deaths [5]. Efforts to eliminate SARS-  
12 CoV-2 would be unsuccessful in the long term, as they are constantly challenged by births of  
13 new susceptible hosts and waning immunity in previously infected individuals. The durability of  
14 SARS-CoV-2 immunity is not yet fully established [6], but births will promote virus survival,  
15 thus, similar to other infectious pathogens, SARS-CoV-2 is likely to circulate in humans for  
16 many years to come [7].

17 An unprecedented effort to develop a vaccine started very early in the pandemic to curb the  
18 current global situation [8]. Research gaps needed to address the response to COVID-19 have  
19 been identified and facilitated work on animal models for vaccine research and development [9].  
20 Different countries and organizations are developing new platform technologies that would  
21 support rapid development of such vaccines from viral sequencing to clinical trials in less than  
22 16 weeks, demonstrate elicitation of consistent immune response, and be suitable for large-scale  
23 production. Of the greatest potential are DNA- and RNA-based vaccine platforms, which can be  
24 developed quickly because they use synthetic processes and do not need cell culture or

1 fermentation, in addition, the use of next-generation sequencing and reverse genetics may also  
2 cut the development time of more conventional vaccines [10, 11]. As per WHO, 149 vaccines are  
3 currently in preclinical development and 38 candidate vaccines are undergoing evaluation in  
4 clinical trials, with multiple vaccines having concluded phase1/2 trials and are already in phase 3  
5 trials. These include JNJ-78436735 an adenovirus vaccine (Ad26.COV2.S)[12][13], mRNA-  
6 1273 an mRNA vaccine[14], AZD1222 an adenovirus vaccine (ChAdOx1 nCoV-19)[15],  
7 BNT162b1an mRNA vaccine[16], NVX-CoV2373 a full-length recombinant SARS CoV-2  
8 glycoprotein nanoparticle vaccine adjuvanted with Matrix M [17], Ad5-nCoV an adenovirus  
9 vaccine [18][19, 20][21]. If one or more of these vaccines are proven to be safe, effective, and  
10 approved by regulatory authorities for usage, it would be unlikely to be widely available with  
11 sufficient quantities to cover the whole population, hence, a phased approach for vaccine  
12 allocation has been developed starting with Phase 1a or “Jumpstart Phase,” targeting high-risk  
13 healthcare workers (HCW) and first responders [22, 23].

14 The Kingdom of Saudi Arabia (KSA) is one of the top thirty countries with the highest reported  
15 COVID-19 cases: 356,911 laboratory confirmed cases and 5,870 deaths [5] as of November 29,  
16 2020. It is also one of the few countries in the world in which a second coronavirus, the Middle  
17 East respiratory syndrome coronavirus (MERS-CoV) is still causing seasonal epidemics since its  
18 discovery in 2012 [24]. As of June 1, 2020, a total of 2,167 laboratory confirmed cases of  
19 MERS-CoV were reported in KSA with 842 deaths [25, 26]. An adenovirus-based vaccine  
20 against MERS-CoV in dromedary camels was recently developed [27]and is currently in phase 3  
21 trials in KSA. Perception, confidence, and hesitancy for newly developed vaccines in the context  
22 of emerging viral infections and pandemics are principal factors in assessing vaccine acceptance.  
23 Acceptance of a potential COVID-19 vaccine assessed among the general population of KSA in

1 a survey of 3,101 participants which showed an acceptance rate of 45% among the general public  
2 [28], while another public survey among 992 participants revealed an acceptance rate of 65%  
3 [29]. However, none of these surveys specifically targeted HCWs who are expected to be  
4 included in the jumpstart phase of vaccination. In this study, we investigated COVID-19 vaccine  
5 perception, acceptance, confidence, hesitancy, and barriers among HCWs in the KSA.

6

## 7 **Methods**

### 8 **Data Collection**

9 This was a national cross-sectional survey among HCWs in KSA during the COVID-19  
10 pandemic. [30] Data were collected between 4 and 14 November 2020. Participants were  
11 recruited from several social media platforms and email lists using a convenience sampling  
12 technique. The survey was a pilot-validated, self-administered questionnaire that was sent to  
13 HCW online through SurveyMonkey®, a platform that allows researchers to deploy and analyze  
14 surveys via the web [31]. The questionnaire was adapted from our previously published study  
15 [26] with modifications and additions related to COVID-19 vaccine candidates.

16 The questions addressed the demographic characteristics of respondents (job category, age, sex,  
17 years of clinical experience, and work area), previous exposure to MERS-CoV or COVID-19  
18 infected patients, and whether HCWs themselves were ever infected with COVID-19.

19 We assessed HCW readiness to receive the COVID-19 vaccine as the main outcome. We also  
20 evaluated the timing of HCW acceptance to receive the vaccine, HCWs' beliefs about COVID-  
21 19 vaccination, and the barriers and reasons for refusal of new vaccines for those who  
22 completely rejected receiving it.

23

1 Additionally, we assessed the HCWs' perceived worry about the COVID19 pandemic using a  
2 series of Likert-like scales (Scale 1–5) and their generalized anxiety level using the general  
3 anxiety disorder-7 (GAD-7). This validated instrument is a seven-item tool that is used to assess  
4 the severity of generalized anxiety disorder, with each item asking the individual to rate the  
5 severity of his or her symptoms over the past two weeks [32]. GAD-7 was previously used to  
6 assess HCWs' anxiety due to COVID-19 [33].  
7 Before participation, the purpose of the study was explained in English at the beginning of the  
8 online survey. The respondent was given the opportunity to ask questions via a dedicated email  
9 address for the study. The Institutional Review Board at the College of Medicine and King Saud  
10 University Medical City approved the study (approval # 20/0065/IRB). A waiver for signed  
11 consent was obtained since the survey presented no more than a minimal risk to subjects and  
12 involved no procedures for which written consent is usually required outside the study context.  
13 To maximize confidentiality, personal identifiers were not required.

14

### 15 **Statistical analysis**

16 Descriptive statistics approaches with mean and standard deviation were applied to continuous  
17 variables, while percentages were used for dichotomous variables. The two-sample t test was  
18 used to evaluate continuous scores, and the chi-squared test ( $\chi^2$ ) of independence was used to  
19 compare proportions.

20 A multivariate binary logistic regression model was used to explore the associations between the  
21 outcome variable of HCWs' willingness to receive the COVID-19 vaccine and demographic  
22 characteristics of HCWs, HCW beliefs toward COVID-19 vaccines and anxiety from COVID-19  
23 and levels of anxiety using the GAD-7. The associations between predictors and the outcome

1 were expressed as adjusted odds ratio and 95% confidence interval. The SPSS IBM Version 21  
2 [34] was used for data analysis, the Excel program was used for creating figures and depictions,  
3 and the p-value  $\leq 0.050$  was considered statistically significant.

4

## 5 **Results**

6 A total of 2,079 HCWs were invited to participate in the study, and 2,007 (96.5%) agreed to  
7 participate. Complete data from 1,512 (75.3%) participants were included in the analysis. The  
8 details of respondents' sociodemographic and professional characteristics are depicted in Table  
9 1. Of the respondents, 360 (23.8%) had one or more chronic illnesses, and 194 (12.8%) reported  
10 a history of COVID-19 infection confirmed by polymerase chain reaction (PCR). Most (86%)  
11 HCWs had been exposed to patients with COVID-19, and almost one third were in contact with  
12 family member(s) who had COVID-19 infection. There were 140 HCWs (12.4%) who reported  
13 contact with MESR-CoV infected patients as well (Supplementary Table S1).

14

### 15 **Acceptance of potential COVID-19 vaccine**

16 Of the 1,512 respondents, 1,058 (70%) were willing to receive a COVID-19 vaccine once  
17 available. In terms of readiness to receive the vaccine immediately, most respondents 795  
18 (52.6%) indicated willingness to receive a vaccine as soon as possible, while 35.6% preferred  
19 waiting for a few months before receiving it and 11.8% indicated they would never accept  
20 receiving any potential vaccine. The majority (83.9%) of respondents reported receiving the  
21 annual influenza vaccine over the last two years (Supplementary Table S1). Moreover, 63.7% of  
22 HCWs also indicated their willingness to receive a MERS-CoV vaccine if it becomes available.  
23 The HCW beliefs about COVID-19 vaccines were evaluated using three statements about the  
24 safety of the vaccine, role of vaccine to stop the pandemic, and role of the vaccine in preventing

1 COVID-19 complications. Most HCWs agreed that a vaccine would be safe and would be the  
2 best way to stop the pandemic and prevent disease complications.  
3 (details are shown in Supplementary Table S2).  
4 Bivariate analysis of participants' characteristics and their willingness to receive COVID-19  
5 vaccines showed a significant correlation with multiple factors (Table 2): male HCWs ( $P =$   
6  $0.0022$ ) and being married but living alone ( $P = 0.016$ ) were significantly associated with  
7 willingness to receive a COVID-19 vaccine. Those who were willing to receive the vaccine had  
8 significantly higher general anxiety scores and specific anxiety from contracting COVID-19  
9 infection or transmitting it to their family members (Table 2). These HCWs significantly agreed  
10 that once a vaccine is available, it would be safe and thought it would be the best way to stop the  
11 pandemic and avoid disease complications.  
12 HCWs working in adult intensive care units and isolation floors were significantly associated  
13 with higher readiness to receive the vaccine ( $p = 0.006$ ). HCWs who took their annual influenza  
14 vaccine in the last two years were significantly more likely to accept COVID-19 vaccines.  
15 Further, HCWs who were willing to receive a MERS-CoV vaccine once available were also  
16 likely to accept the potential COVID-19 vaccine.

17

### 18 **Multivariate analysis of the HCW's willingness to receive a COVID-19 vaccine**

19 The predictors of HWC's willingness to accept a COVID-19 vaccine were analyzed using a  
20 multivariate binary logistic regression. Table 3 shows the adjusted odds ratio for the various  
21 characteristics. Males were 1.55 times more likely to accept a COVID-19 vaccine than females  
22 ( $p = 0.008$ ). Other sociodemographic characteristics, such as age, marital status, previous  
23 personal COVID-19 infection, and presence of chronic medical illness, as well as their clinical

1 role and clinical working area, did not correlate significantly with willingness to receive a  
2 COVID-19 vaccine.

3 The participants' belief in a vaccine's safety once approved by regulatory authorities correlated  
4 significantly with their readiness to accept a vaccine (2.15 times;  $p < 0.001$ ). Likewise, their belief  
5 that a vaccine could stop the COVID-19 pandemic and prevent disease complications correlated  
6 significantly with their willingness to accept a vaccine (1.5 times,  $p < 0.001$ ). By contrast, HCWs  
7 who believed that vaccine candidates were rushed without evidence-informed testing were found  
8 to be 60% less inclined to accept a COVID-19 vaccine once available ( $p < 0.001$ ).

9 Levels of worry about being infected with or transmitting the disease and general anxiety level  
10 did not correlate significantly with willingness to accept a COVID-19 vaccine in multivariate  
11 analysis. Lastly, HCWs who used the Centers for Disease Control and Prevention (CDC)  
12 website to seek evidence-informed knowledge on COVID-19 vaccines were 1.51 times more  
13 likely to accept potential vaccine candidates than HCWs who used other sources of information  
14 ( $p = 0.006$ ).

15

### 16 **Reasons for unwillingness to receive a Covid19 vaccine**

17 Almost 12% of HCWs reported they would never agree to receive any COVID19 vaccine  
18 candidate ( $n=177$ ). When asked for reasons for refusal, the most implicated were inadequate data  
19 on the safety of a new vaccine and concerns of adverse effects (Table 4).

20

21

### 22 **Discussion**

23 Understanding the dynamics of vaccine confidence has always been important for public health  
24 [35] and is now vital in facing the global COVID-19 pandemic. As many vaccines are currently

1 in phase 3 clinical trials, studying the dynamics of vaccine acceptance is important for planning  
2 vaccinations in targeted populations, including HCWs, who would be first to receive the  
3 vaccines once approved by regulatory authorities and the ones to advocate and prescribe them to  
4 their patients.

5 Vaccine hesitancy has been documented as a threat to reducing the burden of infectious diseases  
6 and has been a cause of resurgence of vaccine preventable diseases. In the context of COVID-19,  
7 vaccine hesitancy may cause delays in the acceptance or refusal of new vaccines. In this study,  
8 two-thirds of HCWs expressed willingness to receive a potential COVID-19 vaccine. Cited  
9 concerns for hesitancy were lack of sufficient safety and efficacy data. Other concerns included  
10 potential adverse effects and the belief that a vaccine would be ineffective. Hesitancy is  
11 influenced by factors such as complacency and confidence, which affect vaccine acceptance or  
12 refusal [36]. We found that HCWs expressed their confidence in a vaccine, as 72% thought that  
13 a vaccine would be the most effective way to end the pandemic and 57% thought a vaccine this  
14 soon was a scientific achievement. Complacency relates to the perceived risk of disease, as 20%  
15 of HCWs who would not receive a vaccine indicated they did not perceive themselves at risk of  
16 developing COVID-19 or its complications.

17  
18 Thirty percent of HCWs were not willing to receive any potential COVID-19 vaccine candidate.  
19 These results are consistent with previous research on vaccine confidence for the measles mumps  
20 and rubella vaccine, in which only 64% of general practitioners believed the vaccine was safe,  
21 while 19% did not believe it was important for children. [3]. Similarly, a cross-sectional survey  
22 conducted during the 2009 influenza A (H1N1) pandemic showed an extremely low vaccination  
23 rate of 12.7% among HCWs, with most believing it to be unsafe and ineffective [37]. Another

1 survey among 1,340 HCWs revealed that only 58% were willing to recommend the influenza  
2 vaccine to their diabetic patients [38]. Developing vaccine confidence among HCWs is a major  
3 step in stopping the pandemic amid all the misinformation on different media platforms.  
4 Misinformation and distrust are not new for vaccines; conspiracy theories and suspicions about  
5 vaccines are common throughout many countries over several decades [36, 37]. A coherent,  
6 flexible strategy for COVID-19 vaccination will require unique and collective ingenuity in  
7 addressing the public health and immunization needs of HCWs and their patients [41]. Among  
8 the 30% of HCWs who were hesitant to receive a COVID-19 vaccine, the top reasons for refusal  
9 included the novelty and rapid development of the vaccines and fear of adverse effects, all of  
10 which are key questions to be addressed. [42].

11 Of all the HCWs respondents, 83.9% had received an influenza vaccine, and 63.7% agreed to  
12 receive a MERS-CoV vaccine should it be approved. The overall acceptance rate of 70% to a  
13 COVID-19 vaccine in our current study is close to a previous report of 64.7% acceptance among  
14 all surveyed individuals in KSA [29]. A study from the Republic of Congo showed that only  
15 27.7% of HCWs would accept a COVID-19 vaccine once available [40]. The similarity in  
16 accepting a COVID-19 vaccine between HCWs and the general population was previously  
17 reported in a study from China, with acceptance rates of 76.4% for HCWs and 72.5% in the  
18 general population [44]. These similarities in acceptance rates are interesting and hint that  
19 acceptance may not be influenced by professions. As HCWs are expected to receive any  
20 approved vaccine first, it is clear from these studies that further education is needed to convey  
21 the importance of vaccination and to build confidence to help elevate the acceptance rates among  
22 HCWs.

1 One important finding in our study is that 12.8% of the HCW surveyed had been infected with  
2 COVID-19. In the KSA, there are no published data on the number or percentage of HCWs  
3 among all COVID-19 patients. However, a recent serosurvey showed that the overall  
4 seroprevalence rate was 2.36%. [45] In a systematic review, the overall seroprevalence rate of  
5 COVID-19 among HCWs was about 11% [43].

6 In a multivariate logistic regression analysis, males were more likely to accept COVID-19  
7 compared to females (1.55 times higher), although age, marital state, comorbidity, and clinical  
8 discipline did not converge significantly on their readiness to receive a COVID19 vaccine.  
9 However, in the mentioned study from China, there was no difference in the acceptance rates  
10 between males and females [44]. Another study showed that males were more likely to accept  
11 vaccination (ORa=1.17) [40]. These differences might be related to the heterogeneity of the  
12 populations included in the different studies.

13 An interesting observation in this study is that HCWs' belief in the ability of the vaccine to  
14 reduce COVID-19 complications predicted significantly greater odds of accepting a vaccine.  
15 However, the HCW's mean worry level from contracting COVID-19 disease and infecting  
16 household members did not converge significantly on their odds of willingness to be vaccinated.  
17 Since the confidence and hesitancy of HCWs to vaccines are crucial factors in their likelihood of  
18 being advocates to vaccinating their patients, this and other similar studies highlight the need for  
19 more education and improvement in vaccine confidence among HCW [42].

## 20 **Limitations**

21 There are several limitations to this study. First, it was done using convenience sampling;  
22 therefore, it cannot be generalized to the entire population. However, we believe that national  
23 outreach to recruit HCWs from all regions provides a basis for further national representative

1 studies. Second, this study is subject to the limitations of cross-sectional surveys, including  
2 sampling, response, and recall biases. Lastly, the study was done during a period of heavy media  
3 coverage on potential COVID-19 vaccines, which could influence the levels of knowledge,  
4 perceptions, and attitudes. Despite these limitations, the study highlighted the importance of  
5 addressing HCWs' perceptions and attitudes toward potential COVID-19 vaccines and ensuring  
6 the provision of information from trustable sources, which will contribute to better vaccine  
7 acceptance among HCWs.

8

## 9 **Conclusion**

10 High acceptance of the COVID-19 vaccine has been shown among HCWs. Concerns about  
11 vaccine safety, efficacy, and adverse effects provide important targets for possible interventional  
12 educational programs to enhance vaccination rates. Public health authorities and medical  
13 organizations need to address this principal issue for a successful vaccination campaign. It is  
14 critical that clinicians stay well informed about emerging data on vaccine candidates so that they  
15 can help patients make correct decisions about vaccines that are urgently needed to help end the  
16 pandemic.

17

18

19

20

21

22

23

1 **Tables**

2 **Table 1:** Respondents’ sociodemographic and professional characteristics (N = 1512)

	<b>Frequency (%)</b>
<b>Sex</b>	
Female	944 (62.4)
Male	568 (37.6)
<b>Age (years) mean (SD)</b>	37.28 (8.99)
<b>Age groups</b>	
21-30 years	385 (25.5)
31-40 years	677 (44.8)
41-50 years	298 (19.7)
≥ 50 years	152 (10.1)
<b>Marital state</b>	
Single	435 (28.8)
Married living with family	715 (47.3)
Married but living alone	322 (21.3)
Widowed/Divorced	40 (2.6)
<b>Do have Any chronic illness</b>	
No	1152 (76.2)
Yes	360 (23.8)
<b>Residence</b>	
Riyadh	1092 (72.2)
Other cities	420 (27.8)
<b>Clinical Role</b>	
Physician	637 (42.1)
Nurses and Midwives	757 (50.1)
Technicians, Respiratory Therapists and Pharmacists	118 (7.8)
<b>Hospital Working area</b>	
Intensive care Unit-Pediatrics	115 (7.6)
Intensive care Unit-Adults	216 (14.3)
Emergency Room	152 (10.1)
Hospital General wards	406 (26.9)
Isolation wards	57 (3.8)
Outpatient care areas	319 (21.1)
Specialized units: Radiology, Pharmacy, Dialysis and Lab	206 (13.6)
Hospital administrative/associate/coordinator	41 (2.7)
<b>Hospital type</b>	
Private Sector	350 (23.1)
Public/Governmental	712 (47.1)
University/Academic hospital	450 (29.8)
<b>Hospital setup</b>	
Primary healthcare center	210 (13.9)
Secondary-care hospital	361 (23.9)
Tertiary hospital	941 (62.2)

3

4

5 **Table 2:** Bivariate analysis of healthcare workers’ willingness to receive potential COVID-19  
6 vaccines (N = 1512).

1

Variable	Readiness to receive COVID-19 vaccines (Q14)		
	No (454)	Yes (1058)	p-value
	Number (%)	Number (%)	
<b>Sex</b>			
Female	310 (68.3)	634 (59.9)	0.002
Male	144 (31.7)	424 (40.1)	
<b>Age (years) -mean (SD)</b>	37.37 (9.14)	37.25 (8.92)	0.811
<b>Marital status</b>			
Never married	136 (30)	299 (28.3)	0.016
Married living with family	219 (48.2)	496 (46.9)	
Married living alone	80 (17.6)	242 (22.9)	
Widowed/Divorced	19 (4.2)	21 (2)	
<b>Do you have Any chronic illness</b>			
No	350 (77.1)	802 (75.8)	0.59
Yes	104 (22.9)	256 (24.2)	
<b>Clinical Role</b>			
Physician	186 (41)	451 (42)	0.198
Nurses and Midwives	224 (49.3)	533 (50.4)	
Technicians, Respiratory Therapists and Pharmacists	44 (9.7)	74 (7)	
<b>Hospital Working area</b>			
Intensive care Unit-Pediatrics	32 (7)	83 (7.8)	0.006
Intensive care Unit-Adults	50 (11)	<u>166 (15.7)</u>	
Emergency Room	46 (10.1)	106 (10)	
Hospital General wards	118 (26)	288 (27.2)	
Isolation wards	22 (2.4)	<u>46 (4.3)</u>	
Outpatient care areas	112 (24.7)	207 (19.6)	
Specialized units: Radiology, Pharmacy, Dialysis and Lab	77 (17)	<u>129 (12.2)</u>	
Hospital administrative/associate/coordinator	8 (1.8)	33 (3.1)	
<b>Hospital sector</b>			
Private	118 (26)	232 (21.9)	0.227
Public/Governmental	207 (45.6)	505 (47.7)	
University hospital	129 (28.4)	321 (30.3)	
<b>Health care system</b>			
Primary healthcare center	64 (14.1)	146 (13.8)	0.988

<b>Secondary-care hospital</b>	108 (23.8)	352 (23.9)	
<b>Tertiary hospital</b>	282 (62.1)	659 (62.3)	
<b>Have you been previously in contact with Coronavirus infected patients</b>			
<b>With COVID-Infected Patient</b>			
<b>No</b>	165 (36.3)	370 (35)	0.609
<b>Yes</b>	289 (63.7)	688 (65)	
<b>With COVID-positive family member or friend</b>			
<b>No</b>	344 (75.8)	820 (77.5)	0.463
<b>Yes</b>	110 (24.2)	238 (22.5)	
<b>Yes: With MERS-CoV Patient</b>			
<b>No</b>	414 (61.2)	958 (90.5)	0.693
<b>Yes</b>	40 (8.8)	100 (9.5)	
<b>Never</b>			
<b>Have you been infected with laboratory-confirmed COVID-19 Yourself?</b>			
<b>No</b>	391 (86.1)	927 (87.6)	0.426
<b>Yes</b>	63 (13.9)	131 (12.4)	
<b>Did you take the influenza vaccine during the last 2 years?</b>			
<b>No</b>	120 (26.4)	123 (11.6)	<0.001
<b>Yes</b>	334 (73.6)	935 (88.4)	
<b>If an approved MERS-CoV vaccine became available this year, would you take it yourself?</b>			
<b>No</b>	412 (90.7)	137 (12.9)	<0.001
<b>Yes</b>	42 (9.3)	921 (87.1)	
<b>HCW perceived worries from COVID19 disease and Generalized Anxiety score</b>			
<b>Worry level from contracting COVID19 Infection - 1-5 scale†</b>	2.68 (1.01)	2.87 (1.10)	0.011
<b>Worry level from transmitting the COVID19 Infection to family - 1-5 scale †</b>	3.02 (1.220)	3.20 (1.25)	0.015
<b>Generalized Anxiety total score-mean (SD) GAD-7</b>	4.65 (4.84)	5.32 (5.18)	0.017
<b>Beliefs about the COVID19 Vaccines :</b>			
<b>Once the vaccine is available and approved, it would be safe. mean (SD) agreement</b>	3.1(0.82)	3.9 (0.72)	<0.001
<b>COVID vaccine is the most likely way to stop this pandemic -mean (SD) agreement</b>	3.3 (0.95)	4.2 (0.76)	<0.001
<b>The best way to avoid the complications of COVID is by being vaccinated-mean (SD) agreement</b>	3.1 (0.96)	4 (0.79)	<0.001

1 \*\*Interperion of scale: 1 strongly disagree, 2 disagree, 3 Neither agree nor disagree, 4 Agree, 5 Strongly agree

1 †1-5 rating scale (1 = Not worried at all, 2 = Little worried, 3 = Somewhat worried, 4 = Distressed to 5 = Extremely worried)

2  
3  
4  
5  
6

**Table 3:** Multivariate binary logistic regression analysis of the HCWs’ willingness to get COVID19 vaccine(s) (N=1512)

	Multivariate Adjusted Odds Ratio	95% C.I. for O.R		p-value
		Lower	Upper	
Sex= Male	1.551	1.122	2.144	.008
Age (years)	1.004	.987	1.021	.654
Marital state= Never married	1.084	.803	1.463	.600
Previously infected with COVID19 disease	.897	.605	1.330	.588
Chronic medical disease	1.195	.860	1.660	.289
Clinical Role	.855	.671	1.091	.208
Hospital working area	.958	.894	1.028	.233
Belief in vaccine safety once approved and released (score 1-5)	2.151	1.708	2.708	<0.001
Belief that COVID vaccine is the most likely way to stop the pandemic (score 1-5)	1.539	1.259	1.881	<0.001
Belief that COVID-19 vaccination would be the best way to prevent disease complications (score 1-5)	1.484	1.208	1.823	<0.001
Belief that vaccines are being rushed without testing (score 1-5)	.394	.298	.522	<0.001
Worry level from contracting COVID19 Infection -mean score	1.170	.988	1.387	.069
Worry level from transmitting COVID19 Infection to family - mean score	1.049	.909	1.210	.512
Generalized Anxiety Score (GAD-7) mean score	1.016	.986	1.047	.306
Working in a University Hospital	1.133	.842	1.525	.410
Relies on CDC website for information on COVID19 disease updates.	1.505	1.125	2.013	.006
Constant	.006			<0.001

*Dependent variable= (Willingness to take COVID19 vaccine No/Yes)*

7  
8  
9  
10

**Table 4:** Reasons for unwillingness to receive COVID19 vaccines (N = 177)

Reasons	Number (%)
Inadequate data about the safety of a new vaccine	127 (71.8)
A concern on adverse effects of the vaccine	87 (49.2)
A concern on vaccine being ineffective	35 (19.8)
Prior adverse reaction to any vaccine	28 (15.8)
I am against vaccines in general	24 (13.6)

<b>A concern of acquiring Covid19 infection from the vaccine itself</b>	24 (13.6)
<b>I perceive myself not to be at considerable risk of developing complications if I am infected with Covid19</b>	21 (11.9)
<b>I perceive myself not at elevated risk to acquire Covid19 infection</b>	15 (8.5)
<b>I already had COVID infection</b>	13 (7.3)
<b>Vaccine administration is painful or inconvenient</b>	1 (0.6)

1  
2  
3  
4  
5  
6  
7

### Supplementary materials

**Supplementary Table S1:** Respondents Attitudes toward COVID-19 vaccine and their experience with COVID-19 pandemic. N = 1512

	Frequency	Percentage
<b>Have you been infected with laboratory-confirmed COVID-19 Yourself?</b>		
No	1318	87.2
Yes	194	12.8
<b>Have you been previously in contact with Coronavirus infected patients?</b>		
Yes: With COVID-Infected Patient	977	86
Yes: With COVID-positive family member or friend	348	30.6
Yes: With MERS-CoV Patient	140	12.3
Never	376	24.9
<b>Did you take the influenza vaccine during the last 2 years?</b>		
No	243	16.1
Yes	1269	83.9
<b>If an approved MERS-CoV vaccine became available, would you take it yourself?</b>		
No	549	36.3
Yes	963	63.7
<b>If an approved COVID vaccine became available, would you take it yourself?</b>		
No	454	30

Yes	1058	70
<b>If a COVID vaccine became available, when will you take it?</b>		
Get one as soon as possible	795	52.6
Delay getting it for few months	539	35.6
Never get one	178	11.8

1  
2  
3  
4  
5  
6  
7  
8  
9

Supplementary Table S2: Healthcare workers perceptions/opinion about future COVID-19 vaccines

	N (%)				
<input type="checkbox"/>	Strongly Disagree	Disagree	Undecided	Agree	Strongly Agree
Once the vaccine is available and approved, it will be safe.	20 (1.3)	81 (5.4)	544 (36)	650 (43)	217 (14.4)
COVID-19 vaccine is the most likely way to stop the pandemic.	17 (1.1)	75 (5)	356 (23.5)	627 (41.5)	437 (28.9)
The best way to avoid complications of COVID-19 is by being vaccinated	25 (1.7)	135 (8.9)	389 (25.7)	670 (44.3)	293 (19.4)

10  
11

## 1 **References**

- 2 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019  
3 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. Epub 2020/01/28. doi:  
4 10.1016/S0140-6736(20)30183-5. PubMed PMID: 31986264.
- 5 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with  
6 Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33. Epub 2020/01/25. doi:  
7 10.1056/NEJMoa2001017. PubMed PMID: 31978945; PubMed Central PMCID: PMCPCMC7092803.
- 8 3. Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, et al. The State of  
9 Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. *EBioMedicine*. 2016;12:295-301.  
10 Epub 2016/10/26. doi: 10.1016/j.ebiom.2016.08.042. PubMed PMID: 27658738; PubMed Central  
11 PMCID: PMCPCMC5078590.
- 12 4. Organization WH. WHO Director-General's opening remarks at the media briefing on COVID-19 -  
13 18 March 2020 2020 [5 July 2020]. Available from: [https://www.who.int/dg/speeches/detail/who-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---18-march-2020)  
14 [director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---18-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---18-march-2020).
- 15 5. Hopkins J, Medicine U. Coronavirus resource  
16 center. COVID-19 Map 2020 [Nov 8, 2020]. Available from: <https://coronavirus.jhu.edu/map.html>.
- 17 6. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay  
18 of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl J Med*. 383:2020. p. 1085-7.
- 19 7. Cobey S. Modeling infectious disease dynamics. *Science*. 2020;368(6492):713-4. Epub  
20 2020/04/26. doi: 10.1126/science.abb5659. PubMed PMID: 32332062.
- 21 8. Schwartz JL. Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency,  
22 Scientific Integrity, and Public Trust. *N Engl J Med*. 2020;383(18):1703-5. Epub 2020/09/24. doi:  
23 10.1056/NEJMp2026393. PubMed PMID: 32966716.
- 24 9. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19: towards  
25 controlling of a pandemic. *Lancet*. 2020;395(10229):1015-8. Epub 2020/03/21. doi: 10.1016/s0140-  
26 6736(20)30673-5. PubMed PMID: 32197103; PubMed Central PMCID: PMCPCMC7270596.
- 27 10. Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D.  
28 *Science*. 2020;368(6494):948-50. Epub 2020/05/13. doi: 10.1126/science.abc5312. PubMed PMID:  
29 32393526.
- 30 11. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. *N Engl*  
31 *J Med*. 2020;382(21):1969-73. Epub 2020/04/01. doi: 10.1056/NEJMp2005630. PubMed PMID:  
32 32227757.
- 33 12. Mullard A. COVID-19 vaccine development pipeline gears up. *Lancet*. 2020;395(10239):1751-2.  
34 Epub 2020/06/09. doi: 10.1016/s0140-6736(20)31252-6. PubMed PMID: 32505245; PubMed Central  
35 PMCID: PMCPCMC7272155.
- 36 13. A Study of Ad26.COV2.S for the Prevention of  
37 SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE) 2020 [2 Dec 2020]. Available from:  
38 <https://clinicaltrials.gov/ct2/show/NCT04505722>.
- 39 14. Anderson EJ, Roupheal NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and  
40 Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *N Engl J Med*. 2020. Epub  
41 2020/09/30. doi: 10.1056/NEJMoa2028436. PubMed PMID: 32991794; PubMed Central PMCID:  
42 PMCPCMC7556339.
- 43 15. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and  
44 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase  
45 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396(10249):467-78. Epub 2020/07/24. doi:  
46 10.1016/s0140-6736(20)31604-4. PubMed PMID: 32702298; PubMed Central PMCID:  
47 PMCPCMC7445431.

- 1 16. Walsh EE, Frenck RW, Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and  
2 Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med*. 2020. Epub 2020/10/15.  
3 doi: 10.1056/NEJMoa2027906. PubMed PMID: 33053279; PubMed Central PMCID: PMC7583697.
- 4 17. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2  
5 Recombinant Spike Protein Nanoparticle Vaccine. *N Engl J Med*. 2020. Epub 2020/09/03. doi:  
6 10.1056/NEJMoa2026920. PubMed PMID: 32877576; PubMed Central PMCID: PMC7494251.
- 7 18. Bar-Zeev N, Moss WJ. Encouraging results from phase 1/2 COVID-19 vaccine trials. *Lancet*.  
8 2020;396(10249):448-9. Epub 2020/07/24. doi: 10.1016/s0140-6736(20)31611-1. PubMed PMID:  
9 32702300.
- 10 19. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a  
11 recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a  
12 randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020;396(10249):479-88. Epub  
13 2020/07/24. doi: 10.1016/s0140-6736(20)31605-6. PubMed PMID: 32702299.
- 14 20. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of  
15 a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-  
16 randomised, first-in-human trial. *Lancet*. 2020;395(10240):1845-54. Epub 2020/05/26. doi:  
17 10.1016/s0140-6736(20)31208-3. PubMed PMID: 32450106; PubMed Central PMCID:  
18 PMC7255193.
- 19 21. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine  
20 candidate for SARS-CoV-2. *Science*. 2020;369(6499):77-81. Epub 2020/05/08. doi:  
21 10.1126/science.abc1932. PubMed PMID: 32376603; PubMed Central PMCID: PMC7202686.
- 22 22. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et  
23 al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19  
24 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. *Lancet*.  
25 2020;396(10255):887-97. Epub 2020/09/09. doi: 10.1016/s0140-6736(20)31866-3. PubMed PMID:  
26 32896291; PubMed Central PMCID: PMC7471804.
- 27 23. National Academies of Sciences E, and Medicine. Framework for Equitable Allocation of COVID-  
28 19 Vaccine. Gayle H, Foege W, Brown L, Kahn B, editors. Washington, DC: The National Academies Press;  
29 2020. 260 p.
- 30 24. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel  
31 coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med*. 2012;367(19):1814-20. Epub  
32 2012/10/19. doi: 10.1056/NEJMoa1211721. PubMed PMID: 23075143.
- 33 25. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) 2020  
34 [cited 2020 April 28]. Available from: <https://www.who.int/emergencies/mers-cov/en/>.
- 35 26. Command and Control Center MoH. **National Public Health Events, 2020 - Epi-week 45** [Nov 8,  
36 2020]. Available from: <https://www.moh.gov.sa/en/CCC/Pages/default.aspx>.
- 37 27. Alharbi NK, Qasim I, Almasoud A, Aljami HA, Alenazi MW, Alhafufi A, et al. Humoral  
38 Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary  
39 Camels. *Sci Rep*. 2019;9(1):16292. Epub 2019/11/11. doi: 10.1038/s41598-019-52730-4. PubMed PMID:  
40 31705137; PubMed Central PMCID: PMC6841732 University of Oxford which has commercial rights  
41 to ChAdOx1 MERS. ChAdOx1 MERS vaccine is registered as an IP, number: WO 2018/215766. The  
42 remaining authors declare no potential conflict of interest.
- 43 28. Magadmi RM, Kamel FO. Beliefs and Barriers Associated with COVID-19 Vaccination Among the  
44 General Population in Saudi Arabia. 2020.
- 45 29. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A  
46 Web-Based National Survey. *Journal of Multidisciplinary Healthcare*. 2020;13:1657-63.
- 47 30. Alsubaie S, Hani Temsah M, Al-Eyadhy AA, Gossady I, Hasan GM, Al-Rabiaah A, et al. Middle East  
48 Respiratory Syndrome Coronavirus epidemic impact on healthcare workers' risk perceptions, work and

- 1 personal lives. *J Infect Dev Ctries*. 2019;13(10):920-6. Epub 2020/02/23. doi: 10.3855/jidc.11753.
- 2 PubMed PMID: 32084023.
- 3 31. Regmi PR, Waithaka E, Paudyal A, Simkhada P, van Teijlingen E. Guide to the design and
- 4 application of online questionnaire surveys. *Nepal journal of epidemiology*. 2016;6(4):640-4. doi:
- 5 10.3126/nje.v6i4.17258. PubMed PMID: 28804676.
- 6 32. Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, et al. Validation and
- 7 standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. *Med*
- 8 *Care*. 2008;46(3):266-74. Epub 2008/04/05. doi: 10.1097/MLR.0b013e318160d093. PubMed PMID:
- 9 18388841.
- 10 33. Temsah MH, Al-Sohime F, Alamro N, Al-Eyadhy A, Al-Hasan K, Jamal A, et al. The psychological
- 11 impact of COVID-19 pandemic on health care workers in a MERS-CoV endemic country. *J Infect Public*
- 12 *Health*. 2020;13(6):877-82. Epub 2020/06/09. doi: 10.1016/j.jiph.2020.05.021. PubMed PMID:
- 13 32505461; PubMed Central PMCID: PMCPCMC7256548.
- 14 34. IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.
- 15 35. Larson HJ, Schulz WS, Tucker JD, Smith DM. Measuring vaccine confidence: introducing a global
- 16 vaccine confidence index. *PLoS Curr*. 2015;7. Epub 2015/03/20. doi:
- 17 10.1371/currents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4. PubMed PMID: 25789200; PubMed
- 18 Central PMCID: PMCPCMC4353663.
- 19 36. WHO. Report of the SAGE
- 20 Working Group on Vaccine Hesitancy 2014. Available from:
- 21 [https://www.who.int/immunization/sage/sage\\_wg\\_vaccine\\_hesitancy\\_apr12/en/](https://www.who.int/immunization/sage/sage_wg_vaccine_hesitancy_apr12/en/).
- 22 37. Savas E, Tanriverdi D. Knowledge, attitudes and anxiety towards influenza A/H1N1 vaccination
- 23 of healthcare workers in Turkey. *BMC Infect Dis*. 2010;10:281. Epub 2010/09/25. doi: 10.1186/1471-
- 24 2334-10-281. PubMed PMID: 20863386; PubMed Central PMCID: PMCPCMC3161359.
- 25 38. Ye L, Chen J, Fang T, Cui J, Li H, Ma R, et al. Determinants of healthcare workers' willingness to
- 26 recommend the seasonal influenza vaccine to diabetic patients: A cross-sectional survey in Ningbo,
- 27 China. *Hum Vaccin Immunother*. 2018;14(12):2979-86. Epub 2018/07/19. doi:
- 28 10.1080/21645515.2018.1496767. PubMed PMID: 30020859; PubMed Central PMCID:
- 29 PMCPCMC6343623.
- 30 39. Roberts L. Disease eradication. Killings force rethinking of Pakistan's anti-polio drive. *Science*.
- 31 339. United States 2013. p. 259-60.
- 32 40. Larson HJ, Bhutta ZA. Security, insecurity, and health workers: the case of polio. *JAMA internal*
- 33 *medicine*. 2013;173(15):1393-4.
- 34 41. Larson HJ, Ghinai I. Lessons from polio eradication. *Nature*. 2011;473(7348):446-7. Epub
- 35 2011/05/27. doi: 10.1038/473446a. PubMed PMID: 21614056.
- 36 42. Goodman JL, Grabenstein JD, Braun MM. Answering Key Questions About COVID-19 Vaccines.
- 37 *Jama*. 2020. Epub 2020/10/17. doi: 10.1001/jama.2020.20590. PubMed PMID: 33064145.
- 38 43. Kabamba Nzaji M, Kabamba Ngombe L, Ngoie Mwamba G, Banza Ndala DB, Mbidi Miema J,
- 39 Luhata Lungoyo C, et al. Acceptability of Vaccination Against COVID-19 Among Healthcare Workers in
- 40 the Democratic Republic of the Congo. *Pragmat Obs Res*. 2020;11:103-9. Epub 2020/11/07. doi:
- 41 10.2147/por.s271096. PubMed PMID: 33154695; PubMed Central PMCID: PMCPCMC7605960.
- 42 44. Fu C, Wei Z, Pei S, Li S, Sun X, Liu P. Acceptance and preference for COVID-19 vaccination in
- 43 health-care workers (HCWs). *medRxiv*. 2020.
- 44 45. Alserehi HA, Alqunaiet AM, Al-Tawfiq JA, Alharbi NK, Alshukairi AN, Alanazi KH, et al.
- 45 Seroprevalence of SARS-CoV-2 (COVID-19) among Healthcare Workers in Saudi Arabia: Comparing Case
- 46 and Control Hospitals. *Diagnostic Microbiology and Infectious Disease*. 2020:115273.
- 47 46. Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM, et al. COVID-
- 48 19 in Healthcare Workers: A Living Systematic Review and Meta-analysis of Prevalence, Risk Factors,

- 1 Clinical Characteristics, and Outcomes. Am J Epidemiol. 2020. Epub 2020/09/02. doi:
- 2 10.1093/aje/kwaa191. PubMed PMID: 32870978; PubMed Central PMCID: PMC7499478.
- 3